Sorafenib in adjuvant setting: call for precise and personalized therapy

We read with great interest of the negative result of STORM (1). In the study, 1,114 patients were randomly assigned to sorafenib group and placebo group. After a median duration of treatment of 12.5 months, no difference in median recurrence-free survival (RFS) between the two groups was shown [33.3 months in the sorafenib group vs. 33.7 months in the placebo group; hazard ratio (HR) 0.940; 95% CI: 0.780–1.134; one-sided P=0.26].